Mirtazapin +pharma (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which boosts the release of norepinephrine and serotonin. It also antagonizes postsynaptic 5‑HT2, 5‑HT3 and histamine H1 receptors, producing antidepressant, anxiolytic and sedative effects through enhanced monoaminergic neurotransmission.

The dose of mirtazapine is individualized and set by the prescribing clinician based on the patient’s clinical condition, response, and tolerability. Physicians typically start with a low dose and may adjust gradually, but exact dosing regimens should only be determined by a qualified healthcare professional.

Safety data for mirtazapine during pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks and alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Mirtazapine belongs to the NaSSA class, whereas many first‑line agents are SSRIs or SNRIs. Compared with SSRIs, mirtazapine often causes more sedation and weight gain but may be better tolerated in patients with insomnia or poor appetite. Its distinct receptor profile can be advantageous when other antidepressants have been ineffective.

Mirtazapin +pharma should be stored at ambient temperature, below 25 °C, in the original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiry date printed on the label.

The medication is supplied as oral tablets and is taken by mouth, usually once daily in the evening. It can be taken with or without food, but patients should follow the specific instructions provided by their prescriber to ensure optimal absorption and tolerability.

Serious risks include agranulocytosis or severe neutropenia, serotonin syndrome when combined with other serotonergic drugs, and the emergence or worsening of suicidal thoughts, especially during early treatment. Prompt medical attention is required if any of these events occur.

Mirtazapin +pharma is contraindicated in patients who have taken a monoamine oxidase inhibitor (MAOI) within the past 14 days, those with known hypersensitivity to mirtazapine, and individuals with severe hepatic impairment. Caution is also advised for patients with a history of bipolar disorder, as it may precipitate mania.